The US drug regulator has taken action against the drug company. After this news, the stock fell sharply and a lower circuit was applied on the stock. When there are only buyers of the stock, then an upper circuit is applied on the stock. On the contrary, when there are only sellers of the stock, then a lower circuit is applied on the stock. Keeping the investors in mind, both the exchanges of the country have been changing the circuit filter of the shares from time to time. It should be known that whenever there is a sharp rise or a sharp fall in the shares, the share circuit filter is increased or decreased.

Big news has come about Granules India . As soon as the news came, the stock got a lower circuit. On Tuesday, the stock opened at Rs 596.80 against the closing price of Rs 595.05. After this, the stock got locked at a lower circuit of Rs 535.55.

Important thing for investors-  The stock can go into futures ban. Granules has a 117% position. This means that the stock which can be kept in F&O ban. New and fresh positions are not approved in it for some time. What is the matter- US FDA has issued Form 483 with 6 objections . US FDA has given 'Official Action Indicated' status. Hyderabad unit got 'Official Action Indicated' status from US FDA. This whole matter is about the Gagillapur unit of Granules India. The company told on the exchange that this means action is required. On December 3, it informed the exchanges that the company's Gagillapur facility in Telangana has been put on Official Action Indicated (OAI) by the United States Food and Drug Administration (USFDA). In September this year, the USFDA had issued a Form 483 with six observations for the Gagillapur facility. During the September quarter conference call, the management had indicated resolution of the facility by December. Some of the violations said that equipment and utensils were not cleaned properly, responsibilities and processes applicable to the quality control unit were not followed in writing. The facility was inspected by the USFDA between August 26 and September 6 this year. What will happen now- The company has responded to all the observations issued by the USFDA. In September, CNBC-TV18 had accessed the Form 483 issued to the Gagillapur unit of Granules. The company hopes to resolve the matter soon.